SCHEMBL145708

SCHEMBL145708

COC(=O)c1cc(N2CCCCC2)nc2c1[nH]c1cc(OC)ccc12

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.51
DYRK1A Q13627 3/20 0.50
KDM4E B2RXH2 6/20 0.49
ALDH1A1 P00352 2/20 0.49
EIF2AK2 P19525 1/20 0.46
MAPT P10636 5/20 0.45
NPSR1 Q6W5P4 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GFER P55789 1/20 0.45
HRH4 Q9H3N8 1/20 0.44
HPGD P15428 2/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139554 0.90 JAK2 (0.56) JAK2DYRK1AKDM4EALDH1A1EIF2AK2
SCHEMBL138263 0.79 JAK2 (0.57) JAK2DYRK1AKDM4EALDH1A1EIF2AK2
SCHEMBL141522 0.78 JAK2 (0.80) JAK2DYRK1AKDM4EALDH1A1MAPT
SCHEMBL110525 0.72 PLA2G2A (0.48) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL140965 0.69 JAK2 (0.69) JAK2DYRK1AKDM4EALDH1A1
SCHEMBL144484 0.69 JAK2 (0.80) JAK2DYRK1AKDM4EALDH1A1EIF2AK2
SCHEMBL142902 0.69 JAK2 (0.55) JAK2MAPTMEN1KMT2A
SCHEMBL141886 0.69 JAK2 (0.55) JAK2KDM4EALDH1A1MEN1KMT2A
SCHEMBL142655 0.68 JAK2 (0.78) JAK2DYRK1AKDM4EALDH1A1MAPT
SCHEMBL145362 0.67 JAK2 (0.66) JAK2KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885DYRK1A 317/4885KDM4E 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.